anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants: 14 HIV-uninfected, healthy, male volunteers, ≥18 and ≤49 years of age, will be recruited and enrolled. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests. Participants of all races and ethnicities will be considered for enrollment. This study will be conducted at a single site in the United States: the University of North Carolina at Chapel Hill.

Procedures (methods): An outpatient screening visit will be conducted on all potential participants to obtain informed consent and evaluate for eligibility. Once enrolled, all subjects will take 400 mg oral dose of raltegravir twice daily from Day 1 to Day 7. The healthy men enrolled in this study will undergo single-dose and multiple-dose pharmacokinetic sampling. Blood will be collected via peripheral IV at pre-dose, and at 1, 2, 3, 4, 6, 8 and 12 hours post-dose. Subjects will undergo two colonoscopies during sampling visits (Day 1 and Day 7) for the purpose of obtaining gastrointestinal-associated lymphoid tissue (GALT). Each subject will have his biopsy obtained at one of the following time points post-dose: 1, 2, 3, 4, 6, 8, and 12 hours. Seven to ten days after their last inpatient sampling visit, all subjects will complete a follow-up visit.
The present invention relates to an osteological traditional Chinese medicine which is prepared from 25 traditional Chinese medicines, such as angelica, safflower, sappanwood, frankincense, etc. The effective rate of The present invention is high, the total effective rate can reach 100%, and the healing rate is about 99%. The present invention has the advantages of short course of treatment, obvious effect and no recurrence after healing. Serious patients can be healed in 20 days, and ordinary patients can be healed in about 10 days. The present invention can reach the special functions, namely reaches five nourishments, such as nourishing blood, nourishing qi, nourishing kidneys, nourishing sperma, nourishing power, etc., and has the obvious effect on relieving pain and removing swelling. The present invention has the advantages of convenient admission, simple preparation, reliable technology, low cost, easy acquirement of medicine sources and obvious treatment effect, and furthermore, ordinary patients only use several hundreds of yuan to be healed. The medicine obviously lightens patients' pain after being taken by the patients, the patients can naturally fall asleep, and furthermore, the medicine has the functions of strengthening the body, regenerating muscles, eliminating swelling and relieving pain.
Botulinum toxin (BoNT) injection can safely be done as an office-based procedure, but can be painful itself, especially when injecting pelvic floor muscles to treat chronic pelvic pain (CPP). Mindfulness interventions may reduce procedure-associated acute anxiety and pain. We applied mindfulness techniques to increase the tolerability of office-based pelvic floor BoNT injections in women with CPP. Women enrolled in a clinical trial of BoNT for endometriosis-associated CPP were offered a brief, guided mindfulness session before and/or after transvaginal injection. Anxiety, pain, and dysphoria were rated on a 0-10 numerical rating scale (NRS) before and after each mindfulness session. Eight women underwent mindfulness sessions. Five participants had a session before and two after the transvaginal injection. One participant had two sessions: one before and one after separate injections. All six women completing a session prior to injection had at least moderate anxiety, which lessened after the mindfulness session (median NRS change: -3.3/10). All three women reporting injection-associated pain experienced less intense pain following the post-injection session (median NRS change: -3/10). Three women experiencing dysphoria improved after the session (median NRS change: -3/10). A brief, guided mindfulness session may lessen acute pain, anxiety, and dysphoria associated with office-based transvaginal BoNT injection.
Late-stage HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Patients are randomized to receive either placebo or one of two oral doses of CPI-1189 daily. Patients are assessed for safety and tolerability during Weeks 2, 6, and 10. At Week 10, efficacy assessments are also made. For those who volunteer, a sample of cerebrospinal fluid is obtained at baseline and at Week 10. Blood samples for CPI-1189 pharmacokinetic trough measurements are taken at Weeks 2 and 10. The open-label phase starts at Week 11. At Weeks 13 and 16, a safety evaluation is performed. At the end of the open-label phase, Week 22, a final set of safety and efficacy assessments and a blood sample for CPI-1189 pharmacokinetic trough measurement are obtained.
PROBLEM TO BE SOLVED: To obtain a solid preparation for oral administration having improved solubility of a scarcely soluble drug by using glycyrrhizic acids. SOLUTION: A scarcely soluble drug is dissolved in a solvent such as an alcohol together with one or more substances selected from glycyrrhizic acid, its salt and its ester and the solvent is distilled off to obtain a solid preparation. Preferably, the scarcely soluble drug is dissolved in the solvent, the glycyrrhizic acid is dissolved to the solution and the solvent is distilled off. When the scarcely soluble drug is insoluble in the solvent, it is preferably dissolved by heating. The amount of the glycyrrhizic acid, etc., is 0.5-20 pts.wt. based on 1 pt.wt. of the scarcely soluble drug. The scarcely soluble drug is e.g. a protection factor-type antiulcer agent, a scarcely soluble antiinflammatory agent, a scarcely soluble antiallergic agent, a scarcely soluble local anesthetic agent, etc. The solid preparation has increased absorbability in the body to improve the curative effect and reduce the side actions such as digestive tract mucosa disorder characteristic to antiinflammatory agent in the case of compounding with an antiinflammatory agent.
The present invention relates to a system and method for purchase or booking sessions of cryotherapy as per the preferences of a user using a website and software application hosted on a server. A cryotherapy session request from a patient is received at the software application. The request is transmitted to the server via a network. The server allocates a cryotherapy machine or device and an operator for performing a cryotherapy session at a scheduled place (i.e. remote location) and time. The system allows a patient to select a treatment type, a location, and a time for the cryotherapy session.
PURPOSE: A composition and a cosmetic composition containing Dendrobii Herba ethanol extract are provided to effectively prevent and treat pancreatic cancer. CONSTITUTION: A compositioin for preventing and treating pancreatic cancer contains Dendrobii Herba ethanol extract, prepared using 95% ethanol at 50 Deg. C. for 24 hours. The composition also contains pharmaceutically acceptable carriers or diluents. A cosmetic composition for preventing pancreatic cancer contains the Dendrobii Herba ethanol extract and cosmetologically acceptable cosmetic additives. [Reference numerals] (AA) Relative cell survival rate
The present invention relates to alkoxylated esteramines of Formula (I) and salts thereof. Esteramines according to the present invention may be used in cleaning composition, for example in liquid laundry detergents. They lead to improved cleaning performance of said compositions, for example when used in cold water washing conditions. They surprisingly boost grease cleaning performance of liquid laundry detergents, especially under cold water washing conditions. Whiteness is also improved. The esteramine according to the present invention show improved compatibility in liquid laundry detergent formulations.
<P>PROBLEM TO BE SOLVED: To provide a means for enhancing the effects of cancer thermotherapy and inhibiting the recurrence of the cancer after the thermotherapy in the cancer therapy hardly exhibiting the effects of radiation therapy.  <P>SOLUTION: This medicine for reinforcing cancer thermotherapy contains 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole as an active ingredient. The thermotherapy is preferably a mild hyperthermia at 39 to 42°C, and is preferably carried out prior to a radiation therapy. Cancer to be treated includes preferably cancers caused from lung cancer, pancreatic cancer or liver cancer as a primary cancer. The medicine is preferably a medicine for preventing the recurrence of the cancers.  <P>COPYRIGHT: (C)2008,JPO&INPIT
BACKGROUND: Mechanisms underlying cognitive dysfunction following traumatic brain injury (TBI) partially due to abnormal amyloid processor protein (APP) cleavage and neural hyperactivity. Binding of the extension domain of APP (ExD17) to the GABAbR1 receptor results in reduced neural activity, which might play a role in the mechanisms of cognitive dysfunction caused by TBI.
METHODS: Stretch-induced injury was utilized to establish a cell injury model in HT22 cells. The TBI model was created by striking the exposed brain tissue with a free-falling weight. Topical or intraperitoneal administration of ExD17 was performed. Cell viability was assessed through a cell counting kit-8 assay, while intracellular Ca2+ was measured using Fluo-4. Western blotting was used to investigate the expression of APP amyloidogenic cleavage proteins, GABAbR1, phospholipase C (PLC), PLCB3, and synaptic proteins. ELISA was performed to analyze the levels of Aβ42. Seizures were assessed using electroencephalography (EEG). Behaviors were evaluated through the novel object recognition test, open field test, elevated plus maze test, and nest-building test.
RESULTS: ExD17 improved cell viability and reduced intracellular calcium in the cell injury model. The treatment also suppressed the increased expression of APP amyloidogenic cleavage proteins and Aβ42 in both cell injury and TBI models. ExD17 treatment reversed the abnormal expression of GABAbR1, GRIA2, p-PLCG1/PLCG1 ratio, and p-PLCB3/PLCB3 ratio. In addition, ExD17 treatment reduced neural activity, seizure events, and their duration in TBI. Intraperitoneal injection of ExD17 improved behavioral outcomes in the TBI mouse model.
CONCLUSIONS: ExD17 treatment results in a reduction of amyloidogenic APP cleavage and neuroexcitotoxicity, ultimately leading to an improvement in the behavioral deficits observed in TBI mice.
OBJECTIVE: To evaluate the efficacy of serum myeloperoxidase and lactate dehydrogenase levels as tumour markers in chronic myeloid leukaemia patients after one-year treatment with tyrosine kinase inhibitors.
METHODS: The case-control study was conducted at the College of Medicine, Mustansiriyah University, Baghdad, Iraq, in collaboration with the National Centre of Haematology, Baghdad, from December 2019 to April 2020. The cases comprised chronic myeloid leukaemia patients aged ≥18 years who had completed one-year treatment with tyrosine kinase inhibitor. They were divided into two groups on the basis of major molecular response. Group 1 patients had major molecular response >0.1%, while group 2 patients had major molecular response <0.1%. Group 3 had healthy controls matched for age and gender. Serum myeloperoxidase and lactate dehydrogenase concentrations were measured using enzyme-linked immunosorbent assay. Data was analysed using SPSS 25.
RESULTS: Of the 88 subjects, 32(36.4%) were in group A with mean age 44.9±12.6 years, 26(29.5%) were in group B with mean age 48.23±10.6 years, and 30(34%) were in group C with mean age 43.1±9.3 years. There was a significant increase in myeloperoxidase and lactate dehydrogenase levels in patient groups compared group 3 controls (p<0.05). Between the patient groups 1 and 2, the difference was significant for myeloperoxidase (p<0.05), but not for lactate dehydrogenase (p>0.05).
CONCLUSIONS: There was higher oxidative stress in chronic myeloid leukaemia patients.
Alzheimer's disease remains an unsolved neurological puzzle with no cure. Current therapies offer only symptomatic relief, hindered by limited uptake through the blood-brain barrier. Auranofin, an FDA-approved compound, exhibits potent antioxidative and anti-inflammatory properties targeting brain disorders. Yet, its oral bioavailability challenge prompts the exploration of nanoformulation-based solutions enhancing blood-brain barrier penetrability. The study aimed to investigate the neuroprotective potential of auranofin nanoparticles in streptozotocin-induced AD rats. Auranofin-containing polylactic-co-glycolic acid nanoparticles were formulated by the multiple emulsion solvent evaporation method. Characterization was done by determining entrapment efficiency, particle size distribution, surface charge, and morphology. An in vivo study was performed by administering streptozotocin (3 mg/kg/i.c.v., days 1 and 3), auranofin (5 and 10 mg/kg), auranofin nanoparticles (2.5 and 5 mg/kg), and donepezil (2 mg/kg) for 14 days orally. Behavioral deficits were evaluated using the open field test, Morris water maze, objective recognition test, change in oxidative stress levels, and AD markers in the brain. Following the decapitation of the rats, the brains were excised to isolate the hippocampus. Subsequent analyses included the quantification of biochemical and neuroinflammatory markers, as well as the assessment of neurotransmitter levels. The characterization of auranofin nanoparticles showed an entrapment efficiency of 98%, an average particle size of 101.5 ± 10.3 nm, a surface charge of 27.5 ± 5.10 mV, and a polydispersity index of 0.438 ± 0.12. In vivo, administration of auranofin and auranofin nanoparticles significantly reversed streptozotocin-induced cognitive deficits, biochemical alteration, neuroinflammatory markers, and neurotransmitter levels. The present finding suggests that auranofin nanoparticles have more significant neuroprotective potential than auranofin alone. The therapeutic efficacy may be attributed to its antioxidant and anti-inflammatory properties, as well as its positive neuromodulatory effects. Therefore, our findings suggest that it could be a promising candidate for Alzheimer's disease therapy.
Prepn. of medicaments for oral administration with delayed release, by mixing active components and fats or waxes which can be melted down, in a granulating machine esp. a cog-wheel granulating machine where they are compressed to granulates. The process provides a retard granulate which need not be further melted cooled and milled. Specif. the binding agents used have a melting range of 55-90 degrees C and are milled to a particle size of 125 mu. The active components are milled to a particle size of 20-100 mu. The prefd. process uses 10-30% active component, 50-90% binding agent and 0-40% fillers. The fine powders are mixed and put through a cog-wheel granulating machine which may have hollow perforated cylinders or cylinders with perforated plates inserted. By pressing the mixt. through the perforations, the active component is embedded in the binders.
<P>PROBLEM TO BE SOLVED: To facilitate the identification of output data from a medical image- processing apparatus, to facilitate an image processing and a change processing for the content of the image processing, and at the same time, to prevent an extreme determination or a wrong diagnosis at the time of diagnosing from occurring.  <P>SOLUTION: In a medical image data-outputting process, the control unit 11 of a controller 1 generates output data by applying the image processing to medical image data. At the same time, the control unit 11 generates overlay data based on an image data file ID, reading conditions, and image processing condition numbers, and displays the overlay data on a display unit 13 while superposing the overlay data on the output data. Also, the control unit 11 transmits the output data and the overlay data to a printer 5 through a network N, and prints them, and when the image processing is under a reservation state, a reservation mark is displayed on the top of the output data while superposing them, or printed. In addition, the image data file ID of the medical image data, the reading conditions, the image-processing conditions, and the data of the reservation mark are made to correspond to each other and stored in an image controlling data table.  <P>COPYRIGHT: (C)2003,JPO
Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
FIELD: medicine, gastroenterology, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition using in treatment of pancreas disease and digestion disorders associated with liver diseases. Pharmaceutical composition represents a tablet comprising pancreatin-containing core as an active substance, special additives: lactose, calcium stearate, methylcellulose or hydroxypropyl- methylcellulose and an enterosoluble envelope consisting of acetyl- phthalylcellulose, titanium dioxide, Tween-80, acid red dye 2C taken in the definite ratio of components. Invention provides rise of pancreatin release from tablets. Composition is stable in storage. EFFECT: valuable medicinal and pharmaceutical properties of composition. 2 cl, 1 tbl, 4 ex
BACKGROUND: The lack of transparency is a prevalent issue among the current machine-learning (ML) algorithms utilized for predicting mortality risk. Herein, we aimed to improve transparency by utilizing the latest ML explicable technology, SHapley Additive exPlanation (SHAP), to develop a predictive model for critically ill patients.
METHODS: We extracted data from the Medical Information Mart for Intensive Care IV database, encompassing all intensive care unit admissions. We employed nine different methods to develop the models. The most accurate model, with the highest area under the receiver operating characteristic curve, was selected as the optimal model. Additionally, we used SHAP to explain the workings of the ML model.
RESULTS: The study included 21 395 critically ill patients, with a median age of 68 years (interquartile range, 56-79 years), and most patients were male (56.9%). The cohort was randomly split into a training set (N = 16 046) and a validation set (N = 5349). Among the nine models developed, the Random Forest model had the highest accuracy (87.62%) and the best area under the receiver operating characteristic curve value (0.89). The SHAP summary analysis showed that Glasgow Coma Scale, urine output, and blood urea nitrogen were the top three risk factors for outcome prediction. Furthermore, SHAP dependency analysis and SHAP force analysis were used to interpret the Random Forest model at the factor level and individual level, respectively.
CONCLUSION: A transparent ML model for predicting outcomes in critically ill patients using SHAP methodology is feasible and effective. SHAP values significantly improve the explainability of ML models.
Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
PURPOSE:To easily control check data by displaying the attributes of the check data in a matrix of checking time points and checking items and retrieving and displaying the data corresponding to a position designated on the matrix. CONSTITUTION:When a doctor gives an instruction through a keyboard 1-4 for the start of a health history control program, a list of the health histories of a long period is displayed on a CRT screen for each patient. Then the doctor puts a cursor on a column 5-1 of glycosuria, for example, and clicks the button of a pointing device. The same operations are also given to a column 5-2 for display of the history of blood sugar values. Then the doctor puts the cursor on the checking date columns 5-3 and 5-4 and clicks the button of the pointing device. Thus the check results of the blood pressure, the liver function and the blood lipid of 1986 are displayed on the screen.
Diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. A history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. Caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. Ingestion of barium is not recommended in patients with a history of food aspiration. If barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. If barium is aspirated into the larynx, further administration should be immediately discontinued.

### Information for Patients:

Before administration of this product, patients receiving barium sulfate diagnostic agents should be instructed to:

  1. Inform their physician if they are pregnant.
  2. Inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see PRECAUTIONS-General).
  3. Inform their physician about any other medications they are currently taking.
  4. Seek immediate medical attention if they experience an allergic reaction after using this product.



### Drug Interactions:

The presence of barium sulfate formulations in the GI tract may alter the absorption of therapeutic agents taken concomitantly. In order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.